The myth that a custom drug means approval

FDA is short for the Food and Drug Administration.

Compounding means making or changing a drug for a given need, rather than using a finished product as supplied. A pharmacist or doctor can do this work, as can an outsourcing facility registered with FDA. Such a facility makes batches of sterile medicine, meaning medicine without living germs. FDA’s account sets out the role. Ask what need the proposed drug would meet and why the finished product does not meet it.

A compounded drug is not FDA-approved. Before marketing, it has no FDA review of quality, safety or how well it works. This is the distinction in the November 3, 2026 record. A pharmacy can hold a license while the drug it makes has no approval. Each claim answers a different question.

Work for a named patient has a named route

The route called 503A concerns a drug made for a patient whose name appears on a valid prescription. A pharmacist who holds a license may compound under 503A within a state-licensed pharmacy. Licensed physicians can use the route too, if its other conditions are met. FDA’s framework, checked November 3, 2026, does not treat the prescription alone as enough. Ask which rules apply to the planned drug.

Ask why a finished approved medicine does not meet the named need. Ask for the planned change in plain words. Keep the reason connected to the person’s check, rather than to a menu of options on a page. That makes the question more useful when the prescriber discusses alternatives.

Making batches is a different route

The route called 503B concerns outsourcing facilities: places that make sterile drugs in batches and register with FDA. Sterile means free of living germs. The federal account, checked November 3, 2026, says these places must meet drug-making quality rules and face FDA inspections. Their registration does not give approval to the drugs they make.

Ask which kind of facility would be involved. There is no need to judge the whole arrangement from its size or name. The route, the drug and the reason for using it are separate parts of the answer. The pharmacy briefing covers the state permit question.

The ingredient has to fit the rules

A raw active ingredient is the starting substance meant to do the drug’s work. For the 503A route, it must pass the federal ingredient tests. These were checked November 3, 2026. If a written quality standard called a monograph applies, the ingredient must meet it and the pharmacy compounding standards. If there is no monograph, the next requirement is that an FDA-approved medicine already uses that ingredient. When there is no monograph and no approved medicine uses that ingredient, it needs an entry on FDA’s 503A bulks list, which names allowed raw ingredients. FDA sets out these tests and other conditions.

Ask the prescriber to state the basis for the ingredient being planned. A statement about the facility does not state that basis. Neither does a broad claim that a peptide has been talked about by a committee. The draft-policy briefing covers a conditional enforcement policy: when the Department of Health and Human Services, or HHS, says it does not plan to act on compounding violations. That draft is dated October 30, 2026; it is not a drug approval.

Changing a drug may still count as copying an available medicine

The federal record checked November 3, 2026 sets limits on repeated compounding that amounts to copying a drug already available. Under 503A, to use the exception, the prescriber must find that the change is important for that particular patient. The legal term is significant difference. FDA’s account says adding a vitamin may still leave a drug within the copy definition.

Keep the planned change and its reason together in your notes. Ask how the choice relates to an approved option. A lower quoted fee is a cost question; the drug’s status needs its own answer. It is reasonable to leave the talk with that question still open rather than infer permission from a custom label.